ASR Vermogensbeheer N.V. Acquires Shares of 9,485 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• ASR Vermogensbeheer N.V. acquired 9,485 shares of Regeneron Pharmaceuticals, valued at approximately $6,015,000, during the first quarter.
• Analysts have varying price targets for Regeneron, with Morgan Stanley raising their target to $761.00 and Goldman Sachs reducing theirs to $804.00, indicating a mixed outlook for the stock.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share, significantly beating the analysts' expectations of $8.43, accompanied by a 31.37% net margin.

ASR Vermogensbeheer N.V. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 9,485 shares of the biopharmaceutical company's stock, valued at approximately $6,015,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the period. Costello Asset Management INC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Finally, Curat Global LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $754.00 to $761.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. The Goldman Sachs Group reduced their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. Bank of America reduced their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. Finally, Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $841.30.

Regeneron Pharmaceuticals Price Performance

REGN opened at $555.13 on Thursday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 4.73. The company's 50 day simple moving average is $536.31 and its 200-day simple moving average is $601.45. The stock has a market capitalization of $59.93 billion, a P/E ratio of 13.99, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period last year, the firm earned $11.56 earnings per share. The business's revenue for the quarter was up 3.6% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.